The gastroenterology landscape is evolving rapidly. As healthcare shifts toward value-based care and patient-centered outcomes, innovative therapies that combine clinical efficacy with economic advantage are gaining prominence.
In 2025, Evinature emerged as a noteworthy driver of this evolution, leveraging global gastroenterology conferences to highlight CurQD®, its plant-based nutraceutical protocol designed for inflammatory bowel disease (IBD). Through presentations, posters, and high-level discussions, Evinature reinforced its role at the intersection of biotechnology, clinical research, and cost-conscious care.
Making an Impact at Digestive Disease Week
Digestive Disease Week (DDW) 2025 in San Diego, the largest GI conference in the United States, provided a stage for Evinature to showcase the depth and rigor of its research. Co-founders presented two scientific posters that attracted hundreds of clinicians, pharma executives, and biotech innovators.
The first, a cost-effectiveness analysis co-authored by Prof. Henit Yanai and Dr. David Rubin, underscored CurQD®’s economic value relative to advanced therapies for ulcerative colitis. The study demonstrated meaningful cost savings for both patients and healthcare systems, positioning CurQD® as an effective adjunct therapy without compromising affordability.
The second poster, presented by Nir Salomon and Prof. Shomron Ben-Horin, shared real-world outcomes from Crohn’s disease patients undergoing the CurQD® protocol. The data revealed measurable improvements before, during, and after treatment, offering compelling evidence of the protocol’s practical impact in clinical settings. Beyond the posters, DDW enabled strategic discussions with industry leaders, reinforcing CurQD®’s credibility and expanding its visibility among decision-makers influencing care pathways and insurance coverage.
Connecting with Frontline Clinicians at GHAPP
In September, Evinature shifted its focus to the GHAPP national conference in Las Vegas, a gathering of advanced practice providers (APPs) who manage the day-to-day care of IBD patients. Recognizing that APPs increasingly shape GI clinical management, Evinature designed live sessions and exhibit hall discussions to introduce the CurQD® protocol through real-world use cases.
Attendees learned how to integrate CurQD® into patient workflows, select appropriate protocols, and support adherence, translating research insights into practical clinical guidance. The conference highlighted the protocol’s growing adoption: over 40 U.S. medical centers now implement CurQD®, supporting thousands of patients under clinician guidance. GHAPP underscored the importance of engaging the clinician workforce at the forefront of IBD care, ensuring that evidence-based nutraceutical options like CurQD® are accessible where they can make the most difference.
Momentum from Advances in IBD (AIBD)
The influence of the Advances in IBD (AIBD) 2024 conference carried well into 2025, as CurQD® continued to feature prominently in discussions among leading experts. The protocol was mentioned multiple times in keynote presentations, including data highlighting improvements in response rates, reductions in bowel urgency, multicenter combination therapy outcomes, and pediatric safety profiles. Thought leaders such as Dr. Maia Kayal, Dr. Bruce Sands, Dr. Dawn Beaulieu, and Dr. David Rubin spotlighted CurQD® as a safe, clinically effective adjunct therapy within modern IBD management strategies.
National media recognized these achievements, with Gastroenterology & Hepatology highlighting CurQD®’s efficacy data and patient-centered outcomes. Prof. Shomron Ben-Horin noted that these milestones reflect a decade of rigorous research culminating in a globally validated plant-based therapeutic option.
Establishing Scientific Credibility and Driving Adoption
Evinature’s conference presence in 2025 marked a turning point. By consistently presenting robust clinical and economic evidence at high-profile gatherings, the company has solidified its reputation as a scientific contributor in gastroenterology. Healthcare systems and insurers are taking note, with clinical adoption accelerating across the United States. CurQD® has moved beyond its status as a research-backed nutraceutical to become a widely recognized adjunctive protocol within modern GI practice.
Shaping the Future of Integrative GI Care
As Evinature looks ahead, the company is focused on expanding clinical partnerships, publishing new research, and participating in additional conferences worldwide. With CurQD® gaining recognition for its blend of efficacy, safety, and economic value, Evinature is redefining what it means to provide evidence-based, integrative care for IBD. The company’s efforts illustrate a broader trend in gastroenterology: the convergence of innovation, clinical science, and practical value, ultimately improving outcomes for patients and healthcare systems alike.
